EFFECTIVENESS AND SAFETY OF FIRST-LINE BEVACIZUMAB PLUS FOLFIRI IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)

被引：0
|
作者：
Pinto, Ana Catarina [1 ]
Teixeira, Margarida [1 ]
Bonito, Nuno [1 ]
Jacinto, Paula [1 ]
Ribeiro, Joao [1 ]
Gervasio, Helena [1 ]
机构：
[1] EPE Coimbra, Med Oncol Serv, Portuguese Inst Oncol Francisco Gentil, Coimbra, Portugal
来源：
ANNALS OF ONCOLOGY | 2011年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：v98 / v98
页数：1
相关论文
共 50 条
  • [1] Effectiveness and Safety of Bevacizumab(BV) plus FOLFIRI as First-Line Metastatic Colorectal Cancer (mCRC) Treatment: ETNA Cohort Study
    Fourrier-Reglat, A.
    Rouyer, M.
    Benichou, J.
    Balestra, A.
    Bernard, M. A.
    Grelaud, A.
    Smith, D.
    Ravaud, A.
    Moore, N.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 : S28 - S28
  • [2] VEGF GENE POLYMORPHISMS IN THE PREDICTION OF BENEFIT FROM FIRST-LINE FOLFIRI PLUS BEVACIZUMAB (BV) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS)
    Loupakis, F.
    Ruzzo, A.
    Salvatore, L.
    Canestrari, E.
    Cremolini, C.
    Masi, G.
    Schirripa, M.
    Spoto, C.
    Galluccio, N.
    Vincenzi, B.
    Santini, D.
    Bencardino, K.
    Ricci, V
    Catalano, V
    Manzoni, M.
    Danova, M.
    Tonini, G.
    Magnani, M.
    Falcone, A.
    Graziano, F.
    [J]. ANNALS OF ONCOLOGY, 2009, 20
  • [3] VEGF gene polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts)
    Loupakis, F.
    Ruzzo, A.
    Salvatore, L.
    Canestrari, E.
    Cremolini, C.
    Santini, D.
    Bencardino, K.
    Manzoni, M.
    Falcone, A.
    Graziano, F.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 357 - 357
  • [4] Effectiveness and safety of first-line bevacizumab plus FOLFIRI in elderly patients with metastatic colorectal cancer: Results of the ETNA observational cohort
    Rouyer, Magali
    Fourrier-Reglat, Annie
    Smith, Denis
    Becouarn, Yves
    Guimbaud, Rosine
    Tubiana-Mathieu, Nicole
    Robinson, Philip
    Jove, Jeremy
    Grelaud, Angela
    Noize, Pernelle
    Moore, Nicholas
    Ravaud, Alain
    [J]. JOURNAL OF GERIATRIC ONCOLOGY, 2016, 7 (03) : 187 - 194
  • [5] A COMPARISON OF XELIRI PLUS BEVACIZUMAB WITH FOLFIRI PLUS BEVACIZUMAB AS FIRST-LINE SETTING IN PATIENTS WITH METASTATIC COLORECTAL CANCER
    Ahmet, Bilici
    Uygun, Kazim
    Kaya, Serap
    Ustaalioglu, Bala Basak Oven
    Yildiz, Ramazan
    Temiz, Suleyman
    Seker, Mesut
    Aksu, Gorkem
    Cabuk, Devrim
    Gumus, Mahmut
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 98 - 99
  • [6] Prospective evaluation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI plus bevacizumab (BV).
    Cremolini, Chiara
    Loupakis, Fotios
    Yang, Dongyun
    Salvatore, Lisa
    Zhang, Wu
    Wakatsuki, Takeru
    Schirripa, Marta
    Lonardi, Sara
    Antoniotti, Carlotta
    Aprile, Giuseppe
    Masi, Gianluca
    Graziano, Francesco
    Ruzzo, Annamaria
    Lucchesi, Sara
    Ronzoni, Monica
    Maus, Martin Karl Herbert
    Bocci, Guido
    Tonini, Giuseppe
    Falcone, Alfredo
    Lenz, Heinz-Josef
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment
    Huang, Ching-Wen
    Yeh, Yung-Sung
    Ma, Cheng-Jen
    Tsai, Hsiang-Lin
    Chen, Chao-Wen
    Huang, Ming-Yii
    Lu, Chien-Yu
    Wu, Jeng-Yih
    Wang, Jaw Yuan
    [J]. CHEMOTHERAPY, 2017, 62 (01): : 80 - 84
  • [8] Effectiveness and safety of bevacizumab plus FOLFIRI in first-line metastatic colorectal cancer (mCRC) after 24 months of follow-up for the ETNA cohort study
    Smith, D.
    Rouyer, M.
    Becouarn, Y.
    Michel, P.
    Guimbaud, R.
    Tubiana-Mathieu, N.
    Viret, F.
    Ravaud, A.
    Moore, N.
    Fourrier-Reglat, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] A comparison of efficacy of first-line chemotherapy regimens for metastatic colorectal cancer (mCRC): FOLFIRI plus bevacizumab vs. XELIRI plus bevacizumab
    Ocvirk, J.
    Rebersek, M.
    Boc, M.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 336 - 336
  • [10] Safety analysis of first-line bevacizumab plus chemotherapy in patients with metastatic colorectal cancer (mCRC) participating in a US registry
    Kozloff, M.
    Cohn, A.
    Christiansen, N.
    Flynn, P.
    Kabbinavar, F.
    Robles, R.
    Ulcickas-Yood, M.
    Sarkar, S.
    Hambleton, J.
    Grothey, A.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 173 - 173
12345